Using historical lesion volume data in the design of a new phase II clinical trial in acute stroke

Stroke

Volumn 40, Issue 4, 2009, Pages 1347-1352

  Whitehead, John ^a   Bolland, Kim ^b   Valdès Márquez, Elsa ^b   Lihic, Anela ^c   Ali, Myzoon ^d   Lees, Kennedy ^d  

^a LANCASTER UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF READING   (United Kingdom)

^c Xigen Pharmaceuticals   (Switzerland)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Magnetic resonance imaging scan; Phase II trial; Sample size; Stroke database

Indexed keywords

PLACEBO;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIMULATION; STROKE; VASCULAR LESION; ACUTE DISEASE; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER SIMULATION; FACTUAL DATABASE; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; RANDOMIZED CONTROLLED TRIAL; RISK; SAMPLE SIZE; STANDARD; STATISTICAL MODEL;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; CLINICAL TRIALS, PHASE II AS TOPIC; COMPUTER SIMULATION; DATABASES, FACTUAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MODELS, STATISTICAL; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE; STROKE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 65249087297     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.531442     Document Type: Article

References (16)

1. National Institute of Neurological Diseases and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW, for the stroke-acute Ischemic NXY Treatment (SAINT 1) Trial Investigators. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588-600.
3. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Diener HC, Ashwood T, Wasiewski WW, Emeribe U, for the SAINT II Trial Investigators. NXY-059 for the treatment of acute ischemic stroke. N Eng J Med. 2007;357:562-571.
4. Lees KR, Asplund K, Carolei A, Davis SM, Diener H-C, Kaste M, Orgogozo J-M, Whitehead J. Glycine antagonist (gavestinel) in neuro-protection (GAIN International) in patients with acute stroke: a randomised controlled trial. Lancet. 2000;355:1949-1954.
5. Schwamm LH, Koroshetz WJ, Sorensen AG, Wang B, Copen WA, Budzik R, et al. Time course of lesion development in patients with acute stroke: serial diffusion- and hemodynamic-weighted magnetic resonance imaging. Stroke. 1998;29:2268-2276.
6. Kalowska E, Rostrup E, Rosenbaum S, Petersen P, Paulson OB. Acute MRI changes in progressive ischemic stroke. Eur Neurol. 2008;59: 229-236.
7. Grotta JC, Jacobs TP, Koroshetz WJ, Moskowitz MA. Stroke program review group: an interim report. Stroke. 2008;39:1364-1370.
8. Ali M, Bath PMW, Curram J, Davis SM, Diener H-C, Donnan GA, Fisher M, Gregson B, Grotta J, Hacke W, Hennerici MG, Hommel M, Kaste M, Marler JR, Sacco RL, Teal P, Wahlgren N-G, Warach S, Weir CJ, Lees KR. The Virtual International Stroke Trials Archive. Stroke. 2007;38: 1905-1910.
9. McCullagh P. Regression models for ordinal data. J R Stat Soc B. 1980;43:109-142.
10. Whitehead J. Sample size calculations for ordered categorical data. Stat Med. 1993;12:2257-2271.
11. Saver JL, Johnston KC, Homer D, Wityk R, Koroshetz W, Truskowski LL, Haley EC, for the RANTTAS Investigators. Infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials. Stroke. 1999;30:293-298.
12. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. Effect of intravenous recombinant tissue plasminogen activator on ischemic stroke lesion size measured by computed tomography. Stroke. 2000;31:2912-2919.
13. Stroke Therapy Academic Industry Roundtable II (STAIR II). Recommendations for clinical trial evaluation of acute stroke therapies. Stroke. 2001;32:1598-1606.
14. Hutton JL. Number needed to treat: properties and problems. J R Stat Soc A. 2000;163:403-419.
15. Barber PA, Parsons MW, Desmond PM, Bennett DA, Donnan GA, Tress BM, Davis SM. The use of PWI and DWI in the design of 'proof-of-concept' stroke trials. J Neuroimaging. 2004; 14:123-132.
16. MR Stroke Collaborative Group. Proof-of-principle phase II MRI studies in stroke. Stroke. 2006;37:2521-2525.